Saving with Steve, October 20, 2026

Saving With Steve with Steve Sexton

Weight-Loss Drug Safety, Compounded GLP-1 Risks and Legal Liability with Rusty Reynolds

Steve Sexton talks with personal injury attorney Rusty Reynolds about the hidden risks of compounded and unapproved GLP-1 weight-loss drugs, who can be held responsible when patients are injured, and closes solo with a warning on Treasury yields and market concentration.

Welcoming Rusty Reynolds And The GLP-1 Topic Steve Sexton opens the Saving with Steve Show by thanking his growing international audience before introducing the topic: the explosive growth of weight-loss injections and whether patients truly know what is inside the vials they use. He notes that federal regulators are confronting compounded drugs, illicit GLP-1 products and purported versions of experimental medications never approved for human use, and asks who could be responsible if a questionable product causes serious injury. He introduces personal injury attorney Rusty Reynolds, founder and partner of the Reynolds and Reynolds Law Firm, correcting himself after briefly calling the firm by the wrong name. Reynolds thanks him and says he is glad to be here. Sexton recalls hearing about people who painlessly lost their eyesight from these treatments, setting up a conversation about trust, regulation and the chain of responsibility behind compounded weight-loss drugs reaching consumers nationwide.

Compound Pharmacies And The Question Of Trust Reynolds explains that patients rarely know what is truly in a vial until an injury forces a diagnosis, so the real issue is trust rather than certainty. He describes two kinds of compound pharmacies in the United States, the batch-style 503A pharmacies regulated by the FDA and the 503B pharmacies that customize medication per patient prescription. When demand for a brand-name drug outpaces supply, compounders are permitted to recreate the formula from raw ingredients without deviating from the recipe, a workaround around patent protections meant to let supply catch up with demand. Reynolds says many compounders rush to meet that need without the pharmaceutical-grade capacity of the brand names, raising risk. He advises patients to work through their primary care physician, who knows their history and medications, rather than through social media sellers or gyms that may not know or care about a patient's full medical picture before dispensing a compound.

Unapproved Peptides Like Retatrutide Sexton asks about retatrutide, a drug not yet approved for human use that lawsuits allege is already being sold to consumers. Reynolds explains that many peptides and variations circulating online lack the testing and reliable scientific study that approved GLP-1 drugs have undergone. He says the supplement and peptide industry borrows the trust people place in doctors, hospitals and nurses, often the highest trust many carry, and transfers it to unproven products promising vague benefits like feeling or looking better. Sexton notes that price plays a role too, since GLP-1 drugs that once cost roughly a thousand dollars have fallen toward one or two hundred dollars, or even less, as competition grows. Reynolds warns that unusually cheap pricing should raise the same question as any too-good-to-be-true offer, since producing a pure compound that matches a brand-name recipe carries real costs, and shortcuts taken to hit a lower price point are exactly what can introduce contamination or toxicity.

Eyesight Loss, Gastrointestinal Harm And Hidden Risk After a break, Sexton returns to the injuries patients report, starting with painless vision loss, which Reynolds calls the most prominent case his firm has forensically investigated by preserving and testing the actual vial used. He explains that GLP-1 drugs can worsen pre-existing conditions, describing how diabetics or pre-diabetics with hardened arteries can experience a sudden blood pressure or fluid shift that starves the optic nerve and caus